Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pediatric Prozac Phase IV Commitments Will Test Exclusivity Incentive

Executive Summary

Lilly's Phase IV commitments for additional research on pediatric use of Prozac will serve as a high-profile test of FDA's pediatric exclusivity incentive

You may also be interested in...

Pediatric Prozac clears FDA

FDA clears Lilly's Prozac (fluoxetine) for treatment of major depressive disorder and obsessive compulsive disorder in children seven to 17 Jan. 3. The company received additional market exclusivity from February 2001 until August 2001 for conducting the pediatric trials. As a Phase IV postmarketing commitment, Lilly will "evaluate any potential impact of fluoxetine on long-term growth in children," an FDA 1talk paper says...

Pediatric Bill Toll-Free Adverse Event Hotline Is Of Concern To Pharmacy

The retail pharmacy trade associations are urging the House leadership to delete language creating an adverse event reporting hotline from the pediatric exclusivity bill

House Commerce oversight of FDA agenda will be influenced by WLF president and new staffer Slobodin.

HOUSE COMMERCE OVERSIGHT OF FDA AGENDA WILL BE SHAPED BY WLF President and Legal Studies Division General Counsel Alan Slobodin, who is set to become counsel to the House Commerce Committee on Jan. 24. Although an employee of the full committee, Slobodin is likely to play a role in the development of hearings in the Oversight Subcommittee.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts